The corporate parent of Stop & Shop, Giant, Hannaford, and Food Lion will pay $40 million to settle federal claims that its in-store pharmacies systematically overcharged Medicare, Medicaid, and TRICARE by reporting inflated prescription prices, bilking taxpayer-funded healthcare programs out of millions.
Ahold Delhaize USA Inc., headquartered in Quincy, Massachusetts, reached the settlement with the Department of Justice after the government alleged the company's pharmacies submitted higher, pre-discount prices when billing federal programs instead of the discounted "usual and customary" prices they were required to report. The result, federal officials said, was that the government, and by extension, taxpayers, paid more than it should have on prescription drug claims.
The case began with a single whistleblower: Lawrence LaBenne, a former pharmacist at an Ahold Delhaize supermarket in Pennsylvania. LaBenne will receive more than $6 million from the federal share of the settlement for bringing the case forward.
Federal healthcare programs reimburse pharmacies based on reported pricing data. Pharmacies that operate prescription savings programs, offering customers discounted drug prices, are required to report those discounted prices as the "usual and customary" price when submitting claims to Medicare Part D, Medicaid, and TRICARE.
The DOJ alleged that Ahold Delhaize's pharmacies did the opposite. Instead of reporting the lower prices customers actually paid, the pharmacies submitted the higher, pre-discount figures. That gap between what the pharmacy charged and what it told the government it charged meant federal programs overpaid on those claims.
It is a straightforward billing requirement, and a straightforward alleged violation. The company ran a savings program that lowered prices for shoppers, then turned around and billed Uncle Sam at the old, higher rate.
DOJ officials used the settlement to send a pointed warning to the pharmacy industry. Brett A. Shumate, assistant attorney general of the DOJ's Civil Division, laid out the stakes directly:
"Federal healthcare programs rely on pharmacies reporting accurate pricing information used in the applicable payment formulas. If pharmacies report inflated 'usual and customary' prices on claims to federal healthcare programs, the programs pay more than they should on those claims."
Troy Rivetti, U.S. Attorney for the Western District of Pennsylvania, was blunter about the breach of trust involved:
"Pharmacies are trusted with charging the contracted prescription prices to Medicare and Medicaid and not unfairly and unlawfully taking advantage of the government and the public."
Rivetti added that the settlement "confirms that the United States will take all necessary steps to bring to justice dishonest pharmacies." That language, "dishonest pharmacies", is the government's characterization, not a court finding. But the $40 million price tag speaks for itself.
Of the $40 million total, approximately $32.9 million will go to the federal government. The remainder, roughly $7.1 million, will be distributed among states that participated in the case through their Medicaid programs. The DOJ's Civil Division, its Commercial Litigation Branch Fraud Section, and the U.S. Attorney's Office for the Western District of Pennsylvania coordinated the effort, with assistance from the Defense Health Agency, which administers TRICARE.
LaBenne, the whistleblower who started it all, walks away with more than $6 million from the federal portion. For a former pharmacist who saw something wrong and reported it, that is a significant payout, and a reminder that the federal whistleblower framework, whatever its flaws, can produce results when someone on the inside decides to speak up.
The grocery industry has faced growing regulatory and legal pressure in recent years. New Jersey recently moved to ban algorithmic pricing practices at grocery stores, reflecting broader concern about how large chains treat consumers and government programs alike.
Several important questions remain unanswered. The DOJ has not disclosed the time period covered by the alleged inflated billing. It is unclear when the conduct began, when it stopped, or how many individual pharmacy locations were involved across the company's four grocery chains.
The settlement also does not appear to specify whether Ahold Delhaize admitted wrongdoing. In many civil fraud settlements, companies pay large sums while denying the government's allegations, a legal convention that lets corporations move on without a formal finding of liability. Whether that applies here is not addressed in the DOJ's public statements.
Nor is it clear whether the matter is purely civil or whether criminal referrals are pending. The DOJ's language focused on the civil settlement, but the underlying conduct, deliberately misreporting prices to extract higher government reimbursements, raises obvious questions about whether any individual employees or executives face further scrutiny.
Large retail chains have faced a wave of legal and financial accountability issues. Trader Joe's recently settled a $7.4 million case over receipt practices, and other major retailers have confronted their own compliance failures in recent months.
Ahold Delhaize USA is not a small-time operator. The company runs four of the most recognizable grocery brands on the East Coast, Stop & Shop, Giant, Hannaford, and Food Lion. These are stores where millions of Americans buy their food every week. Their pharmacies fill prescriptions for seniors on Medicare, low-income families on Medicaid, and military families covered by TRICARE.
When a company that size submits inflated prices to federal healthcare programs, the damage is not abstract. Medicare Part D covers prescription drugs for more than 50 million seniors. Medicaid serves tens of millions of low-income Americans. TRICARE covers active-duty service members and their families. Every dollar overpaid on a fraudulently inflated pharmacy claim is a dollar unavailable for legitimate care.
The mechanics of the alleged scheme are not complicated. The company offered discounts to customers, a common competitive practice. But federal rules require pharmacies to report those discounted prices when billing the government. Ahold Delhaize's pharmacies allegedly ignored that requirement and billed at the higher rate. The gap between the two prices flowed straight to the company's bottom line, courtesy of the American taxpayer.
Corporate accountability at major retail chains has become an increasingly urgent issue. A Circle K franchisee recently offered payments to customers after a data breach exposed Social Security numbers, underscoring how large retail operations can cause widespread harm when internal controls fail.
Lawrence LaBenne deserves particular attention. He was a pharmacist, not a lawyer, not a federal investigator, not a political appointee. He worked at an Ahold Delhaize supermarket in Pennsylvania and apparently saw pricing practices that did not square with federal billing rules.
Bringing a whistleblower case against a multibillion-dollar corporation is not a casual decision. It carries professional risk, personal stress, and no guarantee of success. LaBenne's case resulted in a $40 million settlement and a personal recovery of more than $6 million. That outcome vindicates his decision, and the federal framework that gives private citizens a financial incentive to report fraud against the government.
The retail sector continues to face financial turbulence and scrutiny from multiple directions. Walmart's stock recently suffered its worst single-day drop in three years, a reminder that even the largest chains operate under intense pressure, pressure that can create incentives to cut corners.
Pharmacy fraud against federal healthcare programs is not new. It is a persistent drain on programs that serve the most vulnerable Americans, the elderly, the poor, and military families. The government's ability to detect and punish this kind of billing manipulation depends heavily on whistleblowers like LaBenne, because the pricing data pharmacies submit is largely self-reported.
That self-reporting system runs on trust. When a company as large as Ahold Delhaize allegedly abuses that trust, it damages not just the federal treasury but the integrity of the system itself. Other pharmacies that follow the rules and report honest prices compete at a disadvantage against those willing to game the billing process.
Rivetti, the U.S. Attorney, framed the settlement as a deterrent. Whether $40 million is enough to deter a company of Ahold Delhaize's size is an open question. For a corporation operating thousands of stores under four major brands, $40 million may register as a cost of doing business rather than a genuine consequence.
That is the core problem with civil settlements in healthcare fraud cases. The money matters, but the absence of individual accountability, no named executives, no criminal charges, no admission of wrongdoing, leaves the public wondering whether the people who designed or approved the billing practices will ever face personal consequences.
Forty million dollars sounds like a lot until you realize it came from a company trusted to fill prescriptions for America's seniors and service members, and that the only reason we know about it is because one pharmacist refused to look the other way.